FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Print or Ty	pe Responses	s)										•					
1. Name and Address of Reporting Person* Grossbard Elliott B					2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle) RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.					3. Date of Earliest Transaction (Month/Day/Year) 05/29/2007								X Officer (give title below) Other (specify below) Sr. VP Medical Development				
(Street) SOUTH SAN FRANCISCO, CA 94080					4. If Amendment, Date Original Filed(Month/Day/Year)							r) (6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui							ired, Disposed of, or Beneficially Owned						
2			2. Transact Date (Month/Da	y/Year)	2A. Deemed Execution Date, any		(Instr. 8)		(A) or Disposed of (Instr. 3, 4 and 5)		of (D)	Beneficia Reported	ant of Securities ally Owned Following d Transaction(s)		Form:	7. Nature of Indirect Beneficial	
					(Month/Day/Year)		ear)	Code	V	Amount	(A) or (D)	Price	(Instr. 3 and 4)			Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Common Stock			05/29/2007				P		2,000	A	\$ 9.6755	2,000			D		
			T					ies Acquir arrants, op		-			y Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day	on 3A. Exec	Deemed cution Da	[e.g.,]		ion	arrants, op 5.	ed, I	tained i form dis Disposed	of, or Botible second Date	eneficiall eurities) 7. Ti Amo Unde Secu	not requitly valid y Owned tle and unt of erlying	8. Price of Derivative Security (Instr. 5)	spond unle	of 10. Owners Form of	Ownersh (Instr. 4)
	security							(A) or Disposed of (D) (Instr. 3, 4, and 5)			4)			Reported Transaction(s (Instr. 4)	or Indir	ect	
						Code	V	(A) (D)	Dat	te ercisable	Expirati Date	ion Title	Amount or Number of Shares				
Repor	ting O	wners															
								Relations	hips								
Reporting Owner Name / Address Direct					or 10	r 10% Officer							r				

Sr. VP Medical Development

Signatures

Grossbard Elliott B

1180 VETERANS BLVD.

/s/Dolly Vance (Attorney-in-Fact)	05/29/2007
**Signature of Reporting Person	Date

Owner

Explanation of Responses:

RIGEL PHARMACEUTICALS, INC.

SOUTH SAN FRANCISCO, CA 94080

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.